This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (48)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Per Hörnsten, MD, PhD; Marianne Keisu, MD; Bengt-Erik Wiholm, MD, PhD

Arch Dermatol. 1990;126(7):919-922.

Abstract
• During the 17-year period 1972 through 1988, a total of seven cases of agranulocytosis associated with the use of dapsone for the treatment of dermatitis herpetiformis were reported in Sweden. The median age of the patients involved was 61 years; three of them were male. The median duration of dapsone treatment was 7 weeks and the daily prescribed dose was 100 mg. Based on sales and prescription data, the crude relative risk of agranulocytosis during dapsone treatment of dermatitis herpetiformis was 50, and the total risk was one case per 3000 patient years of exposure to dapsone. In relation to the number of new cases of dermatitis herpetiformis, agranulocytosis was estimated to develop in 1 of 240 to 425 patients receiving dapsone therapy. Patients should be instructed to seek medical care immediately in case of fever.

(Arch Dermatol. 1990;126:919-922)

Author Affiliations
From the Department of Hematology, Umeå (Sweden) University Hospital (Dr Hörnsten); the Drug Epidemiology Section, Department of Drugs, National Board of Health and Welfare, Uppsala, Sweden (Drs Keisu and Wiholm); and the Department of Clinical Pharmacology, Karolinska Insitutute, Huddinge (Sweden) University Hospital (Drs Keisu and Wiholm).

Footnotes
Accepted for publication January 2, 1990.

Reprint requests to Drug Epidemiology Section, Department of Drugs, National Board of Health and Welfare, S-751 25 Uppsala, Sweden (Dr Keisu).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

In Vivo Metabolism and Final Disposition of a Novel Nonsteroidal Androgen in Rats and Dogs
Perera et al.
Drug Metab. Dispos. 2006;34:1713-1721.
ABSTRACT | FULL TEXT  

PHARMACOKINETICS AND METABOLISM OF A SELECTIVE ANDROGEN RECEPTOR MODULATOR IN RATS: IMPLICATION OF MOLECULAR PROPERTIES AND INTENSIVE METABOLIC PROFILE TO INVESTIGATE IDEAL PHARMACOKINETIC CHARACTERISTICS OF A PROPANAMIDE IN PRECLINICAL STUDY
Wu et al.
Drug Metab. Dispos. 2006;34:483-494.
ABSTRACT | FULL TEXT  

Management of Acquired Bullous Skin Diseases
Fine
NEJM 1995;333:1475-1484.
FULL TEXT  

Is Dermatology Slipping Into Its Anec-dotage?
Webster
Arch Dermatol 1995;131:149-150.
ABSTRACT